<DOC>
	<DOCNO>NCT03056209</DOCNO>
	<brief_summary>The purpose First In Human study investigate safety tolerability KL1333 single oral dose investigate pharmacokinetic characteristic KL1333 single oral dose .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetic Study KL1333 Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>MELAS Syndrome</mesh_term>
	<mesh_term>Mitochondrial Diseases</mesh_term>
	<criteria>19 45 year age time screen Subjects weigh ≥55 ≤90 kg BMI 18 27 kg/m2 Subjects agree voluntarily participate study comply study requirement sign informed consent form inform nature study understand aspect study History clinically significant hepatic , renal , neurologic , immunologic , respiratory , endocrine disease hematologic•oncologic disease , cardiovascular , psychiatric disease History disease surgery gastrointestinal tract could interfere kinetics study drug . Simple hernia repair appendectomy except . History clinically significant relevant allergy/hypersensitivity Blood AST ( SGOT ) , ALT ( SGPT ) &gt; 1.5 upper limit eGFR value ≤90mL/min/1.73m2 Systolic blood pressure &lt; 100 mmHg &gt; 160 mmHg Diastolic blood pressure &lt; 60 mmHg &gt; 100 mmHg Any abnormalities 12lead ECG screen visit Subjects show positive result drug abuse test , history drug abuse within 60 day prior time screen Subjects take prescribed medication oriental medicine within 14 day overthecounter ( OTC ) medication vitamin within 7 day prior dose study drug ( however , subject include criterion meet accord discretion investigator ) Subjects administer investigational product within 3 month first dose study drug Subjects donate whole blood ( 60 day ) partial blood ( 30 day ) , receive blood transfusion Subjects alcohol consistently ( &gt; 21units/week , 1unit=10 g pure alcohol ) able stop drinking alcohol throughout study period Subjects smoke 90 day prior study initiation able stop smoking throughout study period Subjects able stop take grapefruit/caffeine 3 day prior first dose study drug throughout study period Subjects plan pregnancy study period able use establish contraceptive method Subject judge eligible study participation investigator</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Mitochondrial DNA tRNALeu ( UUR ) m.3243A &lt; G Mutation</keyword>
</DOC>